Literature DB >> 569587

6-OHDA lesion to the dorsal noradrenergic bundle alters morphine-induced locomotor activity and catalepsy.

D C Roberts, S T Mason, H C Fibiger.   

Abstract

Rats show an initial depression in locomotor activity in response to doses of morphine greater than 5 mg/kg during the first hour after injection which is followed by a prolonged hyperactive phase. The effect of bilateral 6-hydroxydopamine (6-OHDA) lesions to the dorsal noradrenergic bundle on this biphasic action of morphine was studied. These lesions were found to significantly potentiate the locomotor depressant effects of morphine at 10.0 and 20.0 mg/kg while leaving the subsequent stimulant action of morphine unchanged. The cataleptic action of morphine at 20.0 mg/kg as measured in a separate test was also potentiated. These lesions were found to deplete hippocampal and cortical noradrenaline (NA) to 3% and hypothalamic NA to 32% of control values and also to cause significant increases in cerebellar and spinal NA. These data suggest a role for NA in the depressant effects of morphine but not in its subsequent stimulant actions which appear to be mediated by other neurochemical systems.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 569587     DOI: 10.1016/0014-2999(78)90208-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Effects of morphine on the plus-maze discriminative avoidance task: role of state-dependent learning.

Authors:  C L Patti; S R Kameda; R C Carvalho; A L Takatsu-Coleman; G B Lopez; S T Niigaki; V C Abílio; R Frussa-Filho; R H Silva
Journal:  Psychopharmacology (Berl)       Date:  2005-12-10       Impact factor: 4.530

2.  The effects of intraventricular 6-hydroxydopamine and 5,6-dihydroxytryptamine on morphine induced locomotor stimulation.

Authors:  P Slater; C Blundell
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-07       Impact factor: 3.000

3.  Attenuation of heroin reward in rats by disruption of the mesolimbic dopamine system.

Authors:  C Spyraki; H C Fibiger; A G Phillips
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.